Brian Cheng
Stock Analyst at JP Morgan
(2.35)
# 2,696
Out of 5,111 analysts
74
Total ratings
50.85%
Success rate
-2.29%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $85.68 | +45.89% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.35 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $94.79 | -14.55% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $9.14 | -45.30% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $16.79 | +7.21% | 5 | Nov 6, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $71 → $82 | $79.00 | +3.80% | 1 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $25.97 | -11.44% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $1.47 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.24 | - | 1 | Oct 10, 2025 | |
| ABSI Absci | Initiates: Overweight | n/a | $3.39 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $26.00 | +26.92% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $39.75 | +18.24% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $21.90 | -8.68% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $56.25 | +24.44% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.81 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $22.64 | -2.83% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $27.60 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.44 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $10.82 | +204.99% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.61 | +272.67% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $28.59 | +337.22% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.77 | +1,712.77% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.21 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.50 | +1,112.12% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.21 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.79 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $7.25 | +1,072.41% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.59 | +176.68% | 1 | Aug 3, 2021 |
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $85.68
Upside: +45.89%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $94.79
Upside: -14.55%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $9.14
Upside: -45.30%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $16.79
Upside: +7.21%
Revolution Medicines
Nov 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $79.00
Upside: +3.80%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $25.97
Upside: -11.44%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.47
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.24
Upside: -
Absci
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.39
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $26.00
Upside: +26.92%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $39.75
Upside: +18.24%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $21.90
Upside: -8.68%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $56.25
Upside: +24.44%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.81
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $22.64
Upside: -2.83%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $27.60
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.44
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $10.82
Upside: +204.99%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.61
Upside: +272.67%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $28.59
Upside: +337.22%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.77
Upside: +1,712.77%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.21
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.50
Upside: +1,112.12%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $3.79
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $7.25
Upside: +1,072.41%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.59
Upside: +176.68%